A debriding formulation for use in debridement of a wound, the debriding formulation comprising: (a) a composition in a dry or powdered form comprising: (i) a proteolytic enzyme mixture obtained from bromelain comprising stem bromelain (EC 3.4.22.32), and ananain (EC 3.4.22.31); (ii) a water-soluble gelling agent, wherein the water-soluble gelling agent is other than a cross-linked polymer of acrylic acid, and wherein said water-soluble gelling agent is galactomannan or glucomannan or a combination thereof; (iii) an anti-aggregation agent; (iv) a pH adjusting agent; and (b) water, wherein, prior to use, the composition (a) being admixed with the water (b) to form said debriding formulation characterized by being a homogenous hydrogel having a viscosity in the range of 1,800 Pa·s (1,800,000 centipoise (cP)) to 9,350 Pa·s (9,350,000 cP), measured by an absolute viscometer with plate plate geometry at room temperature, and having a pH ranging from 5.4 to 8.8, wherein the amount of proteins in the debriding formulation ranges from 0.5 % (w/w) to 7 % (w/w) of the total weight of said debriding formulation, wherein said debriding formulation being topically applied to a wound site of a subject in a regimen of up to ten applications during a time period of up to four weeks, and wherein the debriding formulation being maintained in contact with the wound site for at least four hours per application. (a) a composition in a dry or powdered form comprising: (i) a proteolytic enzyme mixture obtained from bromelain comprising stem bromelain (EC 3.4.22.32), and ananain (EC 3.4.22.31); (ii) a water-soluble gelling agent, wherein the water-soluble gelling agent is other than a cross-linked polymer of acrylic acid, and wherein said water-soluble gelling agent is galactomannan or glucomannan or a combination thereof; (iii) an anti-aggregation agent; (iv) a pH adjusting agent; and (i) a proteolytic enzyme mixture obtained from bromelain comprising stem bromelain (EC 3.4.22.32), and ananain (EC 3.4.22.31); (ii) a water-soluble gelling agent, wherein the water-soluble gelling agent is other than a cross-linked polymer of acrylic acid, and wherein said water-soluble gelling agent is galactomannan or glucomannan or a combination thereof; (iii) an anti-aggregation agent; (iv) a pH adjusting agent; and (b) water, wherein, prior to use, the composition (a) being admixed with the water (b) to form said debriding formulation characterized by being a homogenous hydrogel having a viscosity in the range of 1,800 Pa·s (1,800,000 centipoise (cP)) to 9,350 Pa·s (9,350,000 cP), measured by an absolute viscometer with plate plate geometry at room temperature, and having a pH ranging from 5.4 to 8.8, wherein the amount of proteins in the debriding formulation ranges from 0.5 % (w/w) to 7 % (w/w) of the total weight of said debriding formulation, wherein said debriding formulation being topically applied to a wound site of a subject in a regimen of up to ten applications during a time period of up to four weeks, and wherein the debriding formulation being maintained in contact with the wound site for at least four hours per application. wherein, prior to use, the composition (a) being admixed with the water (b) to form said debriding formulation characterized by being a homogenous hydrogel having a viscosity in the range of 1,800 Pa·s (1,800,000 centipoise (cP)) to 9,350 Pa·s (9,350,000 cP), measured by an absolute viscometer with plate plate geometry at room temperature, and having a pH ranging from 5.4 to 8.8, wherein the amount of proteins in the debriding formulation ranges from 0.5 % (w/w) to 7 % (w/w) of the total weight of said debriding formulation, wherein said debriding formulation being topically applied to a wound site of a subject in a regimen of up to ten applications during a time period of up to four weeks, and wherein the debriding formulation being maintained in contact with the wound site for at least four hours per application. <EOS>